Physician profile
George U Char
NPI 1003895970
$997.83
in general payments reported to CMS, 2019-2025
12 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $37.19 · 2021: $46.74 · 2022: $157 · 2023: $226 · 2024: $116 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $135.66 | 2020-2025 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Dompe US, INC. | $120.90 | 2025 | Oxervate |
| Allergan, INC. | $118.81 | 2022 | |
| Amgen INC. | $115.54 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $113.85 | 2023 | Tyrvaya |
| Abbvie INC. | $91.85 | 2023 | Ozurdex |
| Johnson & Johnson Surgical Vision, INC. | $57.21 | 2019-2022 | |
| Alcon Vision LLC | $50.02 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $29.78 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $21.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Char listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.